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Original Article
Histology of Hepatocellular Carcinoma: Association 
with Clinical Features, Radiological Findings, and 
Locoregional erapy Outcomes
Benjamin V. Park1, Ron C. Gaba1, Yu-Hui Huang1, Yi-Fan Chen2, Grace Guzman3, R. Peter Lokken4
1Department of Radiology, Division of Interventional Radiology, University of Illinois Health, 2Center for Clinical and Translational Science, University of 
Illinois at Chicago, 3Department of Pathology, University of Illinois Health, Chicago, IL, USA, 4Department of Radiology and Biomedical Imaging, Division of 
Interventional Radiology, University of California San Francisco, San Francisco, CA, USA.
INTRODUCTION
Histological grades and cytological subtypes of hepatocellular carcinoma (HCC) have been 
established.[1] Previous studies suggest that high tumor grade is associated with tumor recurrence 
and decreased survival after orthotopic liver transplantation (OLT) among patients within Milan 
criteria and higher local tumor progression rates after radiofrequency ablation (RFA) among 
ABSTRACT
Objective: e objective of the study was to investigate whether hepatocellular carcinoma (HCC) histology is 
associated with clinical and computed tomographic/magnetic resonance imaging features and locoregional 
therapy (LRT) outcomes.
Subjects and Methods: is single-center retrospective study included 124 consecutive patients (92 men, 
median age 59 years) with 132 HCC diagnosed by biopsy between 2008 and 2017 before LRT. Patients underwent 
chemoembolization (n = 51, 41%), ablation (n = 41, 33%), yttrium-90 radioembolization (n = 17, 13%), and 
chemoembolization/ablation (n = 15, 12%). Barcelona clinic liver cancer (BCLC) stage was 0/A (n = 48, 38%), 
B (n = 33, 26%), C (n = 27, 22%), and D (n = 16, 13%). Edmondson-Steiner (ES) grade and cytology were 
correlated with baseline features and radiologic response using logistic regression. Time to progression (TTP) and 
transplant-free survival (TFS) were analyzed using Cox proportional hazard models.
Results: High ES grade was associated with α-fetoprotein (AFP) >50 ng/ml (odds ratio [OR] 4.6, 95% confidence 
interval [CI]: 1.5–13.9; P < 0.01), tumor diameter >5 cm (OR 3.1, 95% CI: 1.1–9.0; P < 0.05), infiltrative appearance 
(OR 5.0, 95% CI: 1.5–16.2; P < 0.01), and BCLC Stage C (OR 4.5, 95% CI: 1.3–16.4; P = 0.02). Clear-cell subtype 
was associated with non-viral cirrhosis (OR 5.3, 95% CI: 1.6–17.2; P < 0.01) and atypical enhancement (OR 
3.1, 95% CI: 1.0–9.3; P < 0.05). AFP, BCLC Stage B, and diameter were associated with reduced TTP and TFS 
(P < 0.05). Neither ES grade nor clear-cell subtype was associated with objective response (OR 2.3, 95% CI: 0.7–
7.4; P = 0.15 and OR 1.1, 95% CI: 0.4–3.4; P = 0.87, respectively), TTP (P > 0.20), or TFS (P > 0.90) on univariate 
or stratified analysis.
Conclusion: Histologic grade is associated with aggressive tumor features, while clear-cell HCC is associated with 
non-viral cirrhosis and atypical enhancement. Unlike AFP, BCLC stage, and tumor size, histologic features were 
not associated with LRT outcomes, supporting biopsy deferral for imaging diagnosed HCC.
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Barcelona clinic liver cancer (BCLC) Stage A patients.[2-4] High 
tumor grade on explant is also associated with lack of odds ratio 
(OR) to transcatheter arterial chemoembolization (TACE).[5] 
In regard to cytological subtype, the clear-cell variant has been 
associated with improved survival after surgical resection[6-8] 
though data conflicts.[9,10] However, aforementioned studies 
predominantly include patients with early-stage disease 
and are not fully reflective of HCC populations treated with 
locoregional therapy (LRT). Further, tumor grade on explant 
after LRT may differ from before therapy. ere is also a paucity 
of literature on the prognostic value of cytological subtype in 
patients treated with LRT. is study was undertaken to assess 
the relationship between baseline histological features of HCC 
and clinical stage, computed tomographic (CT) and magnetic 
resonance imaging (MRI) features, and outcomes in patients 
treated with LRT.
SUBJECTS AND METHODS
Study cohort
is single-center retrospective cohort study was approved by 
our Institutional Review Board and in compliance with the 
Health Insurance Portability and Accountability Act, with a 
waiver of informed consent for retrospective review of medical 
records. Consecutive patients (n = 124, mean age 61 years; age 
range 30–85 years) at the University of Illinois Hospital with 
132 percutaneous biopsy-proven HCC who subsequently 
underwent LRT were identified through retrospective chart 
review from 2008 to 2017. e cohort included 92 men with 
mean age of 59 years (range 30–85 years) and 32 women with 
mean age of 65  years (range 47–83  years). LRT modalities 
were transarterial chemoembolization (TACE, n = 51, 41%), 
percutaneous thermal ablation (n = 41, 33%), yttrium-90 
(Y90) radioembolization (n = 17, 13%), and combination 
TACE/ablation (n = 15, 12%). Baseline BCLC stage was 
0/A (n = 48, 38%), B (n = 33, 26%), C (n = 27, 22%), and 
D (n = 16, 13%). Mean tumor diameter was 4.8 cm ± 4.1 cm. 
e most common etiology of HCC was hepatitis C virus 
(38.7%). Ethnicity, gender, age, baseline laboratory values, 
Child-Pugh (CP) class, cirrhosis etiology, and type of LRT 
were tabulated [Table 1]. e mean time from biopsy to LRT 
was 34 days (standard deviation, 60 days).
Locoregional therapies
LRT was performed by board-certified interventional 
radiologists with 2–20 years attending experience. Treatment 
modality was determined based on the BCLC staging 
algorithm and discussion in multidisciplinary tumor 
board. Y90 radioembolization was reserved for patients 
with multifocal and/or infiltrative disease, macrovascular 
invasion, and total bilirubin of <2.0  mg/dL. RFA under 
n (%)
Mean age (range)
60 (30–85)
Gender
Male 92 (74.2)
Female 32 (25.8)
Ethnicity
African-American 34 (27.4)
Caucasian 54 (43.6)
Hispanic 9 (7.3)
Asian 2 (1.6)
Other 25 (20.2)
Diabetes mellitus
Yes 51 (41.1)
No 73 (58.9)
Cirrhosis etiology
HCV 48 (38.7)
HBV 6 (4.8)
ASH 12 (9.7)
NASH 12 (9.7)
Mixed (viral, ASH, and NASH) 38 (30.7)
Other 8 (6.5)
Mean tumor diameter (cm)
4.9±4.1
Tumor diameter (cm)
≤5 87 (71.9)
>5 34 (28.1)
Total number of tumors
1 59 (47.6)
2 27 (21.8)
3 10 (8.1)
4 5 (4.0)
5 1 (0.8)
6 3 (2.4)
>6 19 (15.3)
Within Milan criteria
Yes 65 (52.4)
No 59 (47.6)
AFP, median (IQR) (ng/ml)
13.1 (6.0–44.3)
AFP >50 ng/ml
No 91 (76.5)
Yes 28 (23.5)
Child-Pugh class
A 53 (42.7)
B 56 (45.2)
C 15 (12.1)
BCLC stage
Stages 0, A 48 (38.7)
Stage B 33 (26.6)
Stage C 27 (21.8)
Stage D 16 (12.9)
Locoregional therapy
Y90 17 (13.7)
Table 1: Baseline demographic characteristics.
(Contd...)
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ultrasound (US) and CT guidance was performed using 
14-gauge multi-tined electrodes (Starburst®, Angiodynamics, 
Inc. Latham, NY) per manufacturer protocol. Conventional 
TACE was performed as previously described.[11] ree 
thermal ablations were performed with microwave antennas 
(PR 15, NeuWave Medical, Madison, WI) per manufacturer 
protocol. For Y90 radioembolization, all patients underwent 
planning mesenteric angiography with Tc-99 macroaggregated 
albumin administration and predetermined dose of Y90 was 
administered at lobar (n = 16) or segmental level (n = 1) using 
SIR-Spheres® (n = 13) (SIRTex, Sydney, NSW) or eraspheres® 
(BTG, London, England) (n = 4). For patients treated with 
TACE/ablation, ablation was performed within 24 h of TACE.
Radiological assessment
Baseline contrast-enhanced multiphase CT (n = 74) or 
MR (n = 38) obtained within 1  month before LRT was 
assessed for arterial-phase hyperenhancement, venous or 
delayed phase washout, delayed capsular enhancement, 
macrovascular invasion, and tumor diameter as per Liver 
Imaging Reporting and Data System definitions.[12] Follow-
up CT or MR images were prescribed 1  month after LRT 
and every 3  months thereafter to assess for residual tumor 
or recurrence. Tumor response and progression were 
determined according to modified Response Evaluation 
Criteria in Solid Tumors (mRECIST) by board-certified 
radiologists with 4–9  years attending experience who were 
blinded to histological data.[13] Complete response (CR) and 
partial response (PR) were considered an objective response. 
For patients with more than one CT or MRI before LRT 
(n = 50), tumor volume doubling time was determined based 
on the Schwartz equation ([T×log2]/3 × [log(M1)–log(M0)]; 
where, T is the interval in days between two MR or CT 
studies, M0 is the 1st time maximum diameter, M1 is the 2nd 
time maximum diameter).[14] Median value of tumor volume 
doubling time was utilized to dichotomize the variable.[15]
Histological analysis
Percutaneous biopsy specimens were obtained under US 
guidance with an 18-gauge core needle (BioPince™, Argon 
Medical Devices, Frisco, TX) and immediately fixed in 
formalin. Histological analysis was performed by a board-
certified pathologist (G.G). Eight patients (6%) had two 
biopsied HCC; one tumor was randomly selected per 
patient for inclusion in statistical analysis to maintain 
the independence of analyzed observations. Histological 
grade was classified by the Edmondson-Steiner (ES) 
system:[1] Grade  1 (well differentiated), Grade  2 (moderately 
differentiated), Grade  3 (poorly differentiated), and Grade  4 
(pleomorphism). ES grade of 3 or 4 was defined as high 
grade. Cytology was classified as usual, clear, sclerosing, 
sarcomatoid, pleomorphic, fibrolamellar, steatohepatitis, 
or inflammatory type; specimens containing two or more 
subtypes were classified as mixed type.[1] Cytology was further 
categorized into three groups: 100% clear cell, focal clear cell 
(combination of clear cell and other variants), and absence of 
clear-cell components.[8] Architectural subtypes were classified 
as trabecular, pseudoglandular, and solid and specimens 
containing two or more subtypes were classified as mixed.[1]
Clinical outcomes
Primary outcome measures were time to progression (TTP) 
after LRT and transplant-free survival (TFS). TTP was defined 
as the time from LRT to the detection of progression on imaging 
by mRECIST. TFS was defined as time from LRT to death or last 
clinical encounter; patients were censored at time of OLT.
Statistical analysis
Statistical analysis was performed using Statistical Analysis 
System (SAS) (2013, version  9.4; SAS Institute, Cary, NC). 
e association between two measurements was assessed 
on univariate analysis and by binary or multinomial logistic 
regressions when one of the measures was dichotomized or 
separated into >2 categories, respectively. To examine the 
impact of measurements on TTP and TFS, both univariate 
and stratified Cox proportional hazard models were fitted 
accordingly and Kaplan–Meier curves were created. Two-
sided P < 0.05 was considered statistically significant. A two-
sided P = 0.05–0.10 was considered a statistical trend.
RESULTS
Baseline biopsy and imaging characteristics
Tumors were ES Grade 1 (n = 13, 10.6%), 2 (n = 94, 76.4%), 
or 3 (n = 16, 13%) [Table  2]. Twenty-four specimens 
n (%)
Ablation 41 (33.1)
RFA 38 (30.6)
MWA 3 (2.4)
TACE 51 (41.1)
TACE/ablation 15 (12.1)
TACE/RFA 14 (11.3)
TACE/PEI 1 (0.8)
HBV: Hepatitis B virus, HCV: Hepatitis C virus, 
ASH: Alcoholic steatohepatitis, NASH: Non-alcoholic steatohepatitis, 
AFP: Alpha-fetoprotein, IQR: Interquartile range, MWA: Microwave 
ablation, RFA: Radiofrequency ablation, PEI: Percutaneous ethanol 
injection, TACE: Transarterial chemoembolization, Y90: Yttrium-90, 
BCLC: Barcelona clinic of liver cancer, ethnicity other: Alaska Native, 
Native Hawaiian, unavailable, cirrhosis etiology other: Primary (n=1), 
cryptogenic (n=5), sarcoidosis (n=1), hemochromatosis (n=1)
Table 1: (Continued)
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(20.9%) were comprised entirely of clear cells, 23  (20%) 
with focal clear cell, and 68 (59.1%) contained no clear cells. 
Architectural subtypes were trabecular (n = 44, 37.6%), 
pseudoglandular (n = 31, 26.5%), and solid or mixed solid 
pattern (n = 20, 17.1%). Baseline CT and MR imaging 
features are summarized in Table 2. Median value of tumor 
volume doubling time was 155  days (interquartile range 
[IQR] 100–221 days).
Baseline features associated with high ES grade and clear-
cell cytology by univariate analysis
High ES grade was associated with baseline α-fetoprotein 
(AFP) level >50  ng/ml (OR 4.6, 95% confidence interval 
[CI] 1.5–13.9; P = 0.007), BCLC Stage C (OR 4.5, 95% CI 
1.3–16.4; P = 0.02), tumor diameter >5 cm (OR 3.1, 95% CI 
1.1–9.0; P = 0.035), and infiltrative appearance (OR 5.0, 95% 
CI 1.5–16.2; P = 0.0007) [Table 3]. ere was a trend toward 
shorter tumor volume doubling time (<155 days) with high 
ES grade (P = 0.09). About 100% clear-cell cytological variant 
was associated with non-viral cirrhosis (OR 5.3, 95% CI 1.6–
17.2; P = 0.005) and both 100% clear cell and focal clear cell 
were associated solid architectural subtype (OR 6.3, 95% CI 
1.8–21.9; P = 0.004 and OR 5.5, 95% CI 1.5–19.7; P = 0.009, 
respectively). Atypical contrast enhancement (lacking 
arterial-phase hyperenhancement or washout) was associated 
with 100% clear cell (OR 3.1, 95% CI 1.0–9.3; P = 0.046) but 
not with focal clear cell (OR 1.6, 95% CI 0.5–5.0; P = 0.44) 
in comparison to complete absence of clear cells. A  trend 
was observed of clear-cell HCC being associated with lack of 
arterial-phase hyperenhancement (OR 3.2, 95% CI 0.9–11.1; 
P = 0.07) and comorbid diabetes mellitus (OR 2.6, 95% CI 
1.0–6.7, P = 0.05). Clear-cell HCC was not associated with 
high tumor volume doubling time (OR 0.5, 95% CI 0.1–2.5, 
P = 0.39).
Treatment response
LRT achieved an objective response in 80 (75.4%) of the 106 
tumors, in which follow-up imaging was available. High ES 
grade was not associated with objective response after LRT 
(OR 2.5, 95% CI 0.7–8.4; P = 0.15) by univariate analysis. 
e presence of 100% clear cell (OR 1.1, 95% CI 0.36–3.36; 
P = 0.87) or focal clear cell (OR 1.4, 95% CI 0.5–4.0; P = 0.57) 
on biopsy was not associated with objective response to LRT.
TTP and TFS by univariate and stratified analysis
Median TTP was 178 days (IQR 81–311 days), with overall 
disease progression rate of 59.8% with median follow-up of 
183 days (range: 12–1799 days).
On univariate analysis [Table  4], tumor burden exceeding 
Milan criteria (hazard ratio [HR] 2.6, 95% CI 1.6–4.4; 
P < 0.001), baseline serum AFP level >50 ng/ml (HR 2.5, 95% 
Table 2: Baseline biopsy and imaging characteristics.
n (%)
ES grade
1 13 (10.6)
2 94 (76.4)
3 16 (13.0)
4 0 (0)
Cytologic variant
Usual 64 (55.7)
Clear 24 (20.9)
Sclerosing 1 (0.9)
Inflammatory 1 (0.9)
Fibrolamellar 0 (0)
Pleomorphic 0 (0)
Steatohepatitis 0 (0)
Sarcomatoid 0 (0)
Mixed 25 (21.7)
Architecture subtypes
Trabecular 44 (37.6)
Pseudoglandular 31 (26.5)
Mixed trabecular 22 (18.8)
Solid and mixed solid 20 (17.1)
Clear-cell amount
100% 24 (20.9)
Focal 23 (20.0)
None 68 (59.1)
Microvascular invasion
Yes 5 (9.1)
No 50 (90.9)
Arterial phase hyperenhancement
Yes 81 (82.6)
No 17 (17.4)
Infiltrative appearance
Yes 17 (14.2)
No 103 (85.8)
Washout
Yes 95 (85.6)
No 16 (14.4)
Delayed capsular enhancement
Yes 44 (39.6)
No 67 (60.4)
Macrovascular invasion
Yes 13 (10.7)
No 109 (89.3)
Cytology mixed=Combination of any variant type (usual, 
clear, sclerosing, etc.) Clear cell 100%=Only clear cell, clear 
cell focal=Combination of clear cell+other cytological subtype, 
none=Absence of clear cell. ES: Edmondson-Steiner
CI 1.4–4.4; P = 0.002), BCLC Stage B (HR 3.0, 95% CI 1.6–5.7; 
P < 0.001), infiltrative appearance (HR 2.4, 95% CI 1.2–4.8; 
P = 0.01), and macrovascular invasion (HR 2.9, 95% CI 1.4–6.2; 
P = 0.006) were associated with disease progression. A trend 
was observed of a higher hazard of progression in tumors with 
microvascular invasion (HR 2.5, 95% CI 0.9–6.9; P = 0.08). 
High ES grade (HR 1.5, 95% CI 0.7–3.1; P = 0.33) [Figure 1a] 
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ES grade high versus low 100% clear cell versus none Focal clear cell versus none
OR Significance OR Significance OR Significance
Age 1.0 P=0.25 1.0 P=0.80 1.03 P=0.27
Gender
Male 1.0 1.0 1.0
Female 0.4 P=0.26 1.1 P=0.79 1.2 P=0.71
Ethnicity
American 1.0 1.0 1.0
Caucasian 1.5 P=0.59 1.2 P=0.69 1.6 P=0.44
Other 1.9 P=0.37 0.8 P=0.78 1.6 P=0.46
DM
No 1.0 1.0 1.0
Yes 1.5 P=0.41 2.6 P=0.05 1.4 P=0.48
Cirrhosis etiology
HCV 1.0 1.0 1.0
HBV 1.5 P=0.70 0.0 P=1.0 0.6 P=0.59
ASH 1.3 P=0.74 5.0 P=0.05 0.9 P=0.92
NASH 0.8 P=0.81 7.5 P<0.05 0.6 P=0.59
Mixed 0.7 P=0.61 3.0 P=0.10 0.8 P=0.73
Other 1.1 P=0.92 11.3 P<0.05 2.7 P=0.34
Viral cirrhosis
Yes 1.0 1.0 1.0
No 0.8 P=0.59 5.3 P<0.01 1.0 P=0.95
AFP >50 ng/ml
No 1.0 1.0 1.0
Yes 4.6 P<0.01 0.5 P=0.30 1.5 P=0.49
Child-Pugh class
A 1.0 1.0 1.0
B 0.4 P=0.09 0.7 P=0.43 0.4 P=0.09
C 0.1 P=0.16 0.8 P=0.71 0.2 P=0.14
BCLC stage
0, A 1.0 1.0 1.0
B 1.5 P=0.57 1.5 P=0.52 1.1 P=0.83
C 4.5 P<0.02 1.4 P=0.63 0.3 P=0.15
D 0.3 P=0.44 1.0 P=0.98 0.2 P=0.18
Tumor diameter
≤5 cm 1.0 1.0 1.0
>5 cm 3.1 P<0.05 1.1 P=0.85 1.5 P=0.49
Within Milan criteria
Yes 1.0 1.0 1.0
No 2.0 P=0.21 0.8 P=0.56 0.7 P=0.44
Arterial-phase hyperenhancement
Yes 1.0 1.0 1.0
No 0.7 P=0.69 3.2 P=0.07 1.8 P=0.38
Washout
No 1.0 1.0 1.0
Yes 1.7 P=0.56 0.8 P=0.75 1.1 P=0.86
Delayed capsular enhancement
No 1.0 1.0
Yes 2.2 P=0.17 1.0 P=0.95 1.8 P=0.24
Enhancement pattern
Typical 1.0 1.0 1.0
Atypical 0.4 P=0.33 3.1 P<0.05 1.6 P=0.44
Table 3: Histological associations with baseline characteristics by univariate analysis.
(Contd...)
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and 100% clear-cell variant (HR 1.4, 95% CI 0.8–2.6; P = 0.28) 
[Figure 2a] were not associated with disease progression 
by univariate analysis. High ES grade or 100% clear cell also 
were not associated with progression when stratified by LRT 
modality or BCLC stage [Supplemental Table 1].
Median TFS was 329  days (IQR 184–660  days). At the 
conclusion of the study period, 58 (47%) were alive, 40 (32%) 
were deceased, and 26 (21%) had undergone orthotopic liver 
transplant.
Decreased TFS was observed with baseline tumor diameter 
>5  cm (HR 2.0, 95% CI 1.0–3.8; P = 0.05), tumor burden 
exceeding Milan criteria (HR 3.1, 95% CI 1.6–6.0; P = 0.001), 
CP Class C (HR 2.9, 95% CI 1.1–7.6; P = 0.03), BCLC Stage 
B (HR 3.9, 95% CI 1.7–9.0; P = 0.002), Stage C (HR 2.9, 95% 
CI 1.2–6.9; P = 0.02), Stage D (HR 5.2, 95% CI 1.8–15.0; 
P = 0.002), and macrovascular invasion (HR 3.0, 95% CI 
1.2–7.9; P = 0.02) [Table 4]. In addition, stable or progressive 
disease after LRT was associated with lower TFS (HR 2.4, 
95% CI 1.2–4.9; P = 0.02).
High ES grade (HR 1.0, 95% CI 0.3–2.8, P = 0.96) 
and 100% clear-cell variant (HR 1.02, 95% CI 0.5–2.2, 
P = 0.95) were not associated with TFS on univariate analysis 
[Figures 1b and 2b]. High ES grade and 100% clear cell also 
were not associated with survival stratified by LRT modality 
or BCLC stage [Supplemental Table  1]. When stratified by 
BCLC stage, there was a trend toward longer TFS with 100% 
clear cell in comparison to no clear cell in BCLC Stage B 
patients (HR 3.2, 95% CI 0.9–11.5; P = 0.08).
DISCUSSION
e baseline histological features of HCC underlying 
clinical presentation, radiologic features, and clinical 
outcomes following LRT are not fully understood. Prior 
studies that have demonstrated an association between 
histological subtype of HCC on recurrence and survival 
after resection, RFA, and transplant predominantly represent 
early-stage disease and histological assessment on surgical 
resection specimens or explant.[2-5] In this study, histological 
information was assessed on percutaneous biopsy before 
LRT, and most patients (61%) were BCLC Stage B or 
greater. High tumor grade was significantly associated with 
aggressive tumor features such as large tumor diameter, 
elevated baseline serum AFP, and infiltrative appearance. In 
addition, the clear-cell variant was significantly associated 
with non-viral etiologies of cirrhosis and atypical contrast 
enhancement patterns on CT or MR images. While these 
findings suggest that tumor grade and cytological subtype 
in part underlie differences in baseline clinical and imaging 
features, such conventional histological information on 
percutaneous biopsy did not impart additional prognostic 
information from tumor stage and high-risk imaging 
features.[16]
High ES has been associated with lack of objective response 
after drug-eluting embolic TACE in a retrospective cohort 
study of 93  patients who subsequently underwent OLT; 
however, the majority of patients were early stage, and 
histological differentiation was determined after TACE 
on explant.[5] In this study, no association was observed 
between high ES grade on percutaneous biopsy before LRT 
and objective response (OR 2.3, 95% CI 0.7–7.4; P = 0.15), 
suggesting that the predictive value of ES grade on post-
therapy explant cannot be extrapolated to percutaneous 
biopsy specimens before LRT or patient populations with 
intermediate- or advanced-stage disease.
Poor histologic differentiation was associated with tumor 
diameter >5  cm, infiltrative appearance, and elevated serum 
AFP, supportive of prior studies. AFP is considered to be 
secreted by dedifferentiated HCC,[17] and infiltrative appearance 
on imaging is known to be associated with higher AFP levels 
ES grade high versus low 100% clear cell versus none Focal clear cell versus none
OR Significance OR Significance OR Significance
Macrovascular invasion
No 1.0 1.0 1.0
Yes 2.4 P=0.22 0.7 P=0.63 0.7 P=0.66
Infiltrative appearance
No 1.0 1.0 1.0
Yes 5.0 P<0.01 1.2 P=0.84 1.2 P=0.79
TVDT >155 days
No 1.0 1.0 1.0
Yes 0.2 P=0.09 0.5 P=0.39 2.0 P=0.35
Age: Age at LRT, DM: Diabetes mellitus, ethnicity other: Hispanic, Asian, Alaska Native, Native Hawaiian, unavailable, HBV: Hepatitis B virus, 
HCV: Hepatitis C virus, ASH: Alcoholic steatohepatitis, NASH: Non-alcoholic steatohepatitis, BCLC: Barcelona clinic of liver cancer, Typical 
enhancement pattern: Presence of arterial-phase hyperenhancement and washout, TVDT: Tumor volume doubling time, LRT: Locoregional therapy, 
ES: Edmondson-Steiner, OR: Objective response
Table 3: (Continued)
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and worse survival after intra-arterial therapy.[18] While tumor 
size, infiltrative appearance, and elevated AFP were associated 
with reduced TTP and TFS in this cohort, no such association 
was observed with histological features on univariate 
or stratified analysis. e predictive value of histologic 
differentiation on prognosis was limited by the fact that 70% of 
tumors with elevated AFP (>50 ng/ml), 75% of infiltrative HCC 
tumors, and 76% of tumors >5 cm were histologically low grade 
on percutaneous biopsy in this study. is is consistent with 
a retrospective study of 63 patients showing that tumor grade 
and microvascular invasion did not predict clinical response 
or overall survival after transarterial embolization or TACE in 
50 patients with prior percutaneous core biopsy.[19] While poor 
tumor differentiation has been associated with local tumor 
progression in a study of 95 BCLC Stage 0/A patients treated 
with RFA, these findings are confounded by high-grade tumors 
being larger than low-grade tumors in the cohort and more 
frequent use of internally cooled electrodes with a higher-
powered generator in the low-grade group.[4]
TTP TFS
HR Significance HR Significance
Age 0.97 P<0.05 1.0 P=0.79
Gender
Male 1.0 1.0
Female 0.7 P=0.18 1.0 P=0.93
Ethnicity
African-American 1.0 1.0
Caucasian 1.2 P=0.64 1.5 P=0.31
Other 0.7 P=0.35 0.9 P=0.78
DM
No 1.0 1.0
Yes 0.7 P=0.19 0.9 P=0.78
Cirrhosis etiology
HCV 1.0
HBV 1.5 P=0.45 0.7 P=0.68
ASH 0.8 P=0.52 0.5 P=0.33
NASH 0.4 P=0.11 0.6 P=0.42
Mixed 1.0 P=0.92 1.00 P=0.99
Other 1.6 P=0.36 0.7 P=0.59
Tumor diameter (cm)
≤5 1.0
>5 1.7 P=0.06 2.0 P<0.05
Within Milan criteria
Yes 1.0 1.0
No 2.6 P<0.001 3.1 P<0.001
AFP >50
No 1.0 1.0
Yes 2.5 P<0.005 1.4 P=0.36
Child-Pugh class
A 1.0 1.0
B 1.5 P=0.14 1.3 P=0.41
C 2.1 P=0.13 2.9 P<0.05
BCLC stage
0/A 1.0 1.0
B 3.0 P<0.001 3.9 P<0.005
C 1.6 P=0.15 2.9 P<0.05
D 2.5 P=0.06 5.2 P<0.005
ES grade
Low 1.0 1.0
High 1.5 P=0.33 1.0 P=0.96
Architecture subtypes
Trabecular 1.0 1.0
Mixed trabecular 1.3 P=0.49 0.7 P=0.50
Pseudoglandular 1.0 P=0.89 1.3 P=0.55
Solid and mixed 
solid
1.2 P=0.64 1.5 P=0.37
Clear-cell amount
None 1.0 1.0
Focal 1.0 P=0.91 1.0 P=0.97
100% 1.4 P=0.28 1.0 P=0.95
Microvascular invasion
No 1.0 1.0
Yes 2.5 P=0.08 1.6 P=0.47
Table  4: Time to progression and transplant-free survival by 
Univariate analysis. TTP TFS
HR Significance HR Significance
Arterial phase hyperenhancement
Yes 1.0 1.0
No 0.7 P=0.19 1.1 P=0.75
Infiltrative HCC
No 1.0 1.0
Yes 2.4 P<0.05 1.7 P=0.30
Venous phase washout
No 1.0 1.0
Yes 1.6 P=0.18 1.5 P=0.41
Macrovascular invasion
No 1.0 1.0
Yes 2.9 P<0.01 3.0 P<0.05
Delayed capsular enhancement
No 1.0 1.0
Yes 1.1 P=0.81 0.7 P=0.37
OR after the first LRT
Yes 1.0 1.0
No 2.3 P<0.005 2.1 P<0.05
OR after all LRTs
Yes 1.0
No 2.7 P<0.001 2.4 P<0.05
Progression within 100 days
No - 1.0
Yes - ‑ 5.9 P<0.001
TTP: Time to progression, TFS: Transplant-free survival, HBV: Hepatitis 
B virus, HCV: Hepatitis C virus, ASH: Alcoholic steatohepatitis, 
NASH: Non-alcoholic steatohepatitis, ethnicity other: Alaska native, 
Native Hawaiian, unavailable, cirrhosis etiology other: Primary, 
cryptogenic, sarcoidosis, DM: Diabetes mellitus, BCLC: Barcelona clinic 
liver cancer, ES grade: Edmondson-Steiner grade, LRT: Locoregional 
therapy, OR: Objective response
Table 4: (Continued)
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Clear-cell HCC is distinguished from other variants by clear 
cytoplasm attributed to increased glycogen or lipid contents 
secondary to metabolic changes.[9] Such morphologic and 
metabolic changes may result from differential oncogenic 
process between chronic viral hepatitis and non-viral 
etiologies of cirrhosis such as alcohol and metabolic 
syndrome.[20] Furthermore, clear-cell variant of HCC is 
known to have decreased number of intratumoral arteries 
in association with fatty changes; this is supportive of its 
association with atypical enhancement on CT or MRI in 
this study.[21] A significant association was observed between 
clear-cell variants and the solid architectural subtype, but its 
biological and clinical significance remains to be determined 
in future study.
While poor tumor differentiation is associated with 
recurrence and poor survival after OLT or surgical 
resection,[2,3] the impact of clear-cell HCC on prognosis is 
controversial: Some studies suggest that clear-cell variant 
is associated with longer overall survival,[6-8] while other 
studies found similar survival between clear and non-clear-
cell variant tumors after surgical resection.[9,10] It is postulated 
that longer survival in clear-cell variant is associated with 
relatively low histological grade and capsule formation that 
are favorable for surgery.[7] However, neither tumor grade 
nor clear-cell variant of HCC was associated with disease 
progression or TFS in our cohort after LRT.
Microvascular invasion on explant is strongly correlated with 
recurrence after OLT or surgical resection.[22,23] In this study, 
a trend was observed toward a higher hazard of progression 
in tumors with microvascular invasion but not TFS. e lack 
of observed association in this study may be due to different 
methods to acquire HCC specimens: Percutaneous biopsy 
versus explant or surgical resection. In this cohort, only 
13% of tumors were high ES grade and 9.1% demonstrated 
microvascular invasion on percutaneous core biopsy. In 
contrast, a study comprised 76% BCLC 0/A patients reported 
53% were high ES grade and 51% had microvascular invasion 
on resection.[24] us, the lack of observed association 
between ES grade and microvascular invasion in the 
current study with treatment response, TTP, and TFS may 
Figure 1: (a) Time to progression by Edmondson-Steiner (ES) grade after locoregional therapy. Kaplan–Meier curves of time to progression 
in patients with hepatocellular carcinoma of high ES grade (n = 13, median 118 days) or low ES grade (n = 93, median 182 days) treated with 
locoregional therapy. (b) Transplant-free survival (TFS) by ES grade after locoregional therapy. Kaplan–Meier curves of TFS in patients with 
hepatocellular carcinoma of high ES grade (n = 16, median 346 days) or low ES grade (n = 107, median 322 days) treated with locoregional 
therapy.
a b
Figure  2: (a) Time to progression by clear-cell cytological composition. Kaplan–Meier curves of time to progression in patients with 
hepatocellular carcinoma (HCC) comprised 100% (n = 22, median 223 days), focal (n = 22, median 155 days), no (n = 55, median 178 days) 
clear cells treated with locoregional therapies. (b) Transplant-free survival by clear-cell cytological composition. Kaplan–Meier curves of TFS 
in patients with HCC comprised 100% (n = 24, median 350 days), focal (n = 23, median 429 days), no (n = 68, median 315 days) clear cells 
treated with locoregional therapies.
ba
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be attributable to the intrinsic limitation of percutaneous 
biopsy, where high-grade tumors are frequently misclassified 
as low grade due to sampling error of heterogeneous tumors. 
Prior studies have demonstrated that percutaneous biopsy 
underestimates tumor grade and microvascular invasion 
compared to resection.[25]
is study demonstrates that histological analysis of tumor 
grade can stratify HCC given its association with aggressive 
clinical and radiologic features. However, this study also 
supports the current practice of deferring conventional 
histological analysis before LRT in tumors diagnosed by 
imaging criteria[12] given the lack of independent prognostic 
information imparted by tumor grade and microvascular 
invasion on percutaneous biopsy. Although the prognostic 
value of conventional histological analysis before LRT may 
be limited, immunohistochemistry and genomic sequencing 
analysis of percutaneous biopsy specimens are under active 
investigation and percutaneous biopsy may yet prove critical 
to treatment allocation in the emerging era of precision 
medicine. Certain genetic mutations involved in Wnt/β-
catenin and hypoxia stress response have been associated 
with objective response after transarterial embolization in 
primary and metastatic liver tumors.[26] Furthermore, high 
expression of programmed death ligand-1 on resected HCC 
specimens is associated with poor tumor differentiation, 
elevated AFP, microvascular invasion,[24] and poor disease-
free survival and overall survival.[27,28]
Our study bears several limitations. First, the retrospective 
single-institution design renders potential sampling bias in 
our cohort. Although the majority of tumors in this study 
demonstrated typical arterial-phase hyperenhancement and 
washout, a retrospective study of percutaneously biopsied 
HCC study will be inevitably enriched with HCC with 
non-diagnostic imaging features. Our cohort consisted of 
predominantly Caucasian and African-American patients 
with viral etiologies of HCC, and extrapolation of findings 
to other populations should be performed with caution. 
e relatively low number of patients with high ES grade 
(13%) in this cohort might have increased our susceptibility 
to a type  II error. Similarly, while our study is unique in 
including BCLC B, C, and D patients, the variability in BCLC 
stage and LRT modality may have introduced confounding 
and reduced our ability to observe associations between 
histological features and outcomes. However, numerous 
tumor and clinical features, such as tumor size and BCLC 
stage, were significantly associated with TFS in this study; 
although a larger study may detect an association between 
histologic features on percutaneous biopsy on LRT outcomes, 
it is unlikely that histological features are superior prognostic 
indicators compared to macroscopic tumor features such as 
size and portal vein invasion, and clinical factors including 
BCLC stage. As discussed, studies utilizing percutaneous 
biopsy specimens are prone to histological misclassification 
bias due to non-representative tissue sampling of 
histologically heterogeneous tumors.
CONCLUSION
High histologic grade of HCC on percutaneous biopsy is 
associated with poor prognostic indicators such as larger 
tumors, infiltrative appearance, and advanced BCLC stage. 
e clear-cell variant of HCC was associated with non-viral 
cirrhosis, and the paucity of arteries in this subtype may 
underlie the atypical enhancement associated with these 
tumors. Percutaneous biopsy, therefore, may be used to 
diagnose HCC, but histological stratification did not provide 
independent prognostic information. e findings support 
deferral of percutaneous biopsy and histological assessment 
of HCC diagnosed by imaging criteria before LRT.
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Supplemental Table 1: TTP and TFS for High ES Grade and Clear 
Cell Variant Stratified by LRT Modality and BCLC Stage.
TTP TFS
HR Significance HR Significance
High ES grade  
LRT modality
Y90 - 0.7 P=0.78
Ablation - - - -
TACE 1.5 P=0.38 0.8 P=0.71
TACE/Ablation 2.5 P=0.30 1.5 P=0.71
BCLC Stage
0/A 0.6 P=0.65 2.3 P=0.45
B 1.1 P=0.89 0.5 P=0.46
C/D 1.7 P=0.37 0.6 P=0.51
100% Clear Cell 
Variant
LRT modality
Y90 2.6 P=0.45 1.7 P=0.52
Ablation 1.4 P=0.60 1.2 P=0.87
TACE 0.8 P=0.58 0.8 P=0.66
TACE/Ablation - - - -
BCLC Stage
0/A 1.2 P=0.72 1.7 P=0.54
B 1.0 P=0.96 3.2 P=0.08
C/D 1.3 P=0.63 0.4 P=0.17
TTP: Time to progression, TFS : Transplant-free survival, TACE : 
Transarterial chemoembolization, Y90 : Yttrium-90 radioembolization, 
BCLC : Barcelona Clinic Liver Cancer, -: no results due to limited sample 
size, LRT: Locoregional therapy
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